# Use of Extracorporeal Photopheresis Treatment Over Time (2001–2023) in Alberta, Canada: A Retrospective Cohort Study

**Authors:** Louis Girard, Sylvia Aponte‐Hao, Jason R. Randall, Karen J. B. Martins, Huong Luu, Khanh Vu, Tyler Williamson, Scott W. Klarenbach

PMC · DOI: 10.1002/hsr2.71373 · Health Science Reports · 2025-10-16

## Full-text entities

- **Diseases:** multiple sclerosis (MESH:D009103), lymphoma (MESH:D008223), systemic (MESH:D015619), immunologically mediated disorders (MESH:D007154), Crohn's disease (MESH:D003424), leukocytoclastic vasculitis (MESH:C535509), connective tissue disorder (MESH:D003240), acute and chronic (MESH:D001930), dermatomyositis (MESH:D003882), systemic sclerosis (MESH:D012595), cancer (MESH:D009369), GVHD (MESH:D006086), hypereosiniphilic syndrome (MESH:D013577), CTCL (MESH:D016410)
- **Chemicals:** steroid (MESH:D013256), ultraviolet A (-), ruxolitinib (MESH:C540383), 8-methoxypsoralen (MESH:D008730)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12531099/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12531099/full.md

## References

13 references — full list in the complete paper: https://tomesphere.com/paper/PMC12531099/full.md

---
Source: https://tomesphere.com/paper/PMC12531099